Hims & Hers Health, Inc.'s 10-K, read.

Hims & Hers is growing fast, with nine-month revenue up about 30% to $2.25B and Q3 revenue up about 49%, but the latest 10-Q shows that growth has come with a sharp profitability reversal. Gross margin fell, operating losses replaced profits, operating cash flow declined, and the balance sheet absorbed large acquisition-related obligations and convertible debt, all while the company faces a direct FDA challenge over compounded GLP-1 products.

• Profitability reversal: nine-month operating loss of about $242M versus operating income of about $96M a year earlier, and a nine-month net loss of about $211M versus net income of about $108M.
• Gross margin compression: Q3 gross profit was about 57% of revenue, versus about 74% in the year-earlier quarter, as cost of revenue rose sharply.
• Regulatory exposure: the FDA issued a February 2026 statement intending to restrict GLP-1 active ingredients for non-approved compounded drugs and directly named Hims & Hers, which could hit a meaningful product line.
• Heavy obligations from acquisitions: current deferred acquisition payables of about $479M, plus earn-out liabilities of roughly $171M across current and long-term.
• Leverage and balance sheet strain: convertible senior notes of about $1.37B, and total stockholders' equity down to about $355M from about $541M at year-end 2025.

Not investment advice — general research, the same for every reader. You make your own calls.